We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was up +1.72% at $18.34. This change outpaced the S&P 500's 0.62% gain on the day. At the same time, the Dow added 0.99%, and the tech-heavy Nasdaq gained 0.65%.
The infectious disease drug developer's shares have seen a decrease of 7.01% over the last month, not keeping up with the Medical sector's loss of 1.22% and the S&P 500's gain of 0.59%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $0 million. These results would represent year-over-year changes of +16.33% and 0%, respectively.
Investors should also note any recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 8.89% fall in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 21.99. This expresses a premium compared to the average Forward P/E of 20.46 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 105, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
In the latest close session, Adma Biologics (ADMA - Free Report) was up +1.72% at $18.34. This change outpaced the S&P 500's 0.62% gain on the day. At the same time, the Dow added 0.99%, and the tech-heavy Nasdaq gained 0.65%.
The infectious disease drug developer's shares have seen a decrease of 7.01% over the last month, not keeping up with the Medical sector's loss of 1.22% and the S&P 500's gain of 0.59%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $0 million. These results would represent year-over-year changes of +16.33% and 0%, respectively.
Investors should also note any recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 8.89% fall in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 21.99. This expresses a premium compared to the average Forward P/E of 20.46 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 105, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.